Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Sells $2,602,110.00 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Gary M. Owens sold 21,000 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the completion of the sale, the chief executive officer now directly owns 43,337 shares in the company, valued at $5,369,887.67. This trade represents a 32.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mesa Laboratories Trading Down 2.8 %

MLAB opened at $121.89 on Thursday. Mesa Laboratories, Inc. has a one year low of $83.68 and a one year high of $155.12. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.53 and a current ratio of 0.71. The stock has a market cap of $662.35 million, a price-to-earnings ratio of -2.63 and a beta of 0.82. The stock’s 50 day moving average price is $137.47 and its 200-day moving average price is $129.24.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. On average, equities analysts forecast that Mesa Laboratories, Inc. will post 8 EPS for the current year.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Friday, February 28th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.53%. Mesa Laboratories’s payout ratio is -1.38%.

Hedge Funds Weigh In On Mesa Laboratories

Hedge funds have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Mesa Laboratories by 20.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,103 shares of the medical instruments supplier’s stock valued at $1,312,000 after purchasing an additional 1,708 shares during the period. Barclays PLC lifted its holdings in shares of Mesa Laboratories by 357.4% in the 3rd quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier’s stock worth $1,148,000 after buying an additional 6,905 shares during the period. Geode Capital Management LLC grew its position in shares of Mesa Laboratories by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 124,761 shares of the medical instruments supplier’s stock worth $16,205,000 after buying an additional 5,771 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Mesa Laboratories by 90.3% during the third quarter. Victory Capital Management Inc. now owns 14,001 shares of the medical instruments supplier’s stock valued at $1,818,000 after buying an additional 6,643 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of Mesa Laboratories by 27.8% in the third quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier’s stock valued at $828,000 after acquiring an additional 1,403 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.